Jason L. Townson
University of New Mexico
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jason L. Townson.
Journal of the American Chemical Society | 2013
Jason L. Townson; Yu Shen Lin; Jacob O. Agola; Eric C. Carnes; Hon S. Leong; John D. Lewis; Christy L. Haynes; C. Jeffrey Brinker
The combination of nanoparticle (NP) size, charge, and surface chemistry (e.g., extent of modification with polyethylene glycol (PEG)) is accepted as a key determinant of NP/cellular interactions. However, the influence of spatial arrangement and accessibility of the charged molecules on the NP surface vis-à-vis the average surface charge (zeta (ζ) potential) is incompletely understood. Here we demonstrate that two types of mesoporous silica nanoparticles (MSNP) that are matched in terms of primary and hydrodynamic particle size, shape, pore structure, colloidal stability, and ζ potential, but differ in surface chemistry, viz. the spatial arrangement and relative exposure of surface amines, have profoundly different interactions with cells and tissues when evaluated in vitro and in vivo. While both particles are ∼50 nm in diameter, PEGylated, and positively charged (ζ = +40 mV), PEG-PEI (MSNPs modified with exposed polyamines), but not PEG-NMe3(+) (MSNP modified with distributed, obstructed amines) rapidly bind serum proteins, diverse cells types in vitro, and endothelial and white blood cells in vivo (ex ovo chick embryo model). This finding helps elucidate the relative role of surface exposure of charged molecules vs ζ potential in otherwise physicochemically matched MSNP and highlights protein corona neutrality as an important design consideration when synthesizing cationic NPs for biological applications.
ACS Nano | 2016
Paul N. Durfee; Yu-Shen Lin; Darren R. Dunphy; Ayse Muniz; Kimberly S. Butler; Kevin R. Humphrey; Amanda J. Lokke; Jacob O. Agola; Stanley S. Chou; I-Ming Chen; Walker Wharton; Jason L. Townson; Cheryl L. Willman; C. Jeffrey Brinker
Many nanocarrier cancer therapeutics currently under development, as well as those used in the clinical setting, rely upon the enhanced permeability and retention (EPR) effect to passively accumulate in the tumor microenvironment and kill cancer cells. In leukemia, where leukemogenic stem cells and their progeny circulate within the peripheral blood or bone marrow, the EPR effect may not be operative. Thus, for leukemia therapeutics, it is essential to target and bind individual circulating cells. Here, we investigate mesoporous silica nanoparticle (MSN)-supported lipid bilayers (protocells), an emerging class of nanocarriers, and establish the synthesis conditions and lipid bilayer composition needed to achieve highly monodisperse protocells that remain stable in complex media as assessed in vitro by dynamic light scattering and cryo-electron microscopy and ex ovo by direct imaging within a chick chorioallantoic membrane (CAM) model. We show that for vesicle fusion conditions where the lipid surface area exceeds the external surface area of the MSN and the ionic strength exceeds 20 mM, we form monosized protocells (polydispersity index <0.1) on MSN cores with varying size, shape, and pore size, whose conformal zwitterionic supported lipid bilayer confers excellent stability as judged by circulation in the CAM and minimal opsonization in vivo in a mouse model. Having established protocell formulations that are stable colloids, we further modified them with anti-EGFR antibodies as targeting agents and reverified their monodispersity and stability. Then, using intravital imaging in the CAM, we directly observed in real time the progression of selective targeting of individual leukemia cells (using the established REH leukemia cell line transduced with EGFR) and delivery of a model cargo. Overall, we have established the effectiveness of the protocell platform for individual cell targeting and delivery needed for leukemia and other disseminated disease.
Proceedings of the National Academy of Sciences of the United States of America | 2012
Bryan Kaehr; Jason L. Townson; Robin M. Kalinich; Yasmine H. Awad; B. S. Swartzentruber; Darren R. Dunphy; C. Jeffrey Brinker
Tissue-derived cultured cells exhibit a remarkable range of morphological features in vitro, depending on phenotypic expression and environmental interactions. Translation of these cellular architectures into inorganic materials would provide routes to generate hierarchical nanomaterials with stabilized structures and functions. Here, we describe the fabrication of cell/silica composites (CSCs) and their conversion to silica replicas using mammalian cells as scaffolds to direct complex structure formation. Under mildly acidic solution conditions, silica deposition is restricted to the molecularly crowded cellular template. Inter- and intracellular heterogeneity from the nano- to macroscale is captured and dimensionally preserved in CSCs following drying and subjection to extreme temperatures allowing, for instance, size and shape preserving pyrolysis of cellular architectures to form conductive carbon replicas. The structural and behavioral malleability of the starting material (cultured cells) provides opportunities to develop robust and economical biocomposites with programmed structures and functions.
Oncotarget | 2016
Colleen N. Biggs; Khurram M. Siddiqui; Ali Alzahrani; Siddika Pardhan; Sabine I. Brett; Qiu Q. Guo; Jun Yang; Philipp Wolf; Nicholas Power; Paul N. Durfee; Connor D. MacMillan; Jason L. Townson; Jeffrey Brinker; Neil Fleshner; Jonathan I. Izawa; Ann F. Chambers; Joseph L. Chin; Hon S. Leong
Background Extracellular vesicles released by prostate cancer present in seminal fluid, urine, and blood may represent a non-invasive means to identify and prioritize patients with intermediate risk and high risk of prostate cancer. We hypothesize that enumeration of circulating prostate microparticles (PMPs), a type of extracellular vesicle (EV), can identify patients with Gleason Score≥4+4 prostate cancer (PCa) in a manner independent of PSA. Patients and Methods Plasmas from healthy volunteers, benign prostatic hyperplasia patients, and PCa patients with various Gleason score patterns were analyzed for PMPs. We used nanoscale flow cytometry to enumerate PMPs which were defined as submicron events (100-1000nm) immunoreactive to anti-PSMA mAb when compared to isotype control labeled samples. Levels of PMPs (counts/μL of plasma) were also compared to CellSearch CTC Subclasses in various PCa metastatic disease subtypes (treatment naïve, castration resistant prostate cancer) and in serially collected plasma sets from patients undergoing radical prostatectomy. Results PMP levels in plasma as enumerated by nanoscale flow cytometry are effective in distinguishing PCa patients with Gleason Score≥8 disease, a high-risk prognostic factor, from patients with Gleason Score≤7 PCa, which carries an intermediate risk of PCa recurrence. PMP levels were independent of PSA and significantly decreased after surgical resection of the prostate, demonstrating its prognostic potential for clinical follow-up. CTC subclasses did not decrease after prostatectomy and were not effective in distinguishing localized PCa patients from metastatic PCa patients. Conclusions PMP enumeration was able to identify patients with Gleason Score ≥8 PCa but not patients with Gleason Score 4+3 PCa, but offers greater confidence than CTC counts in identifying patients with metastatic prostate cancer. CTC Subclass analysis was also not effective for post-prostatectomy follow up and for distinguishing metastatic PCa and localized PCa patients. Nanoscale flow cytometry of PMPs presents an emerging biomarker platform for various stages of prostate cancer.
Scientific Reports | 2015
Yan-Ru Lou; Liisa Kanninen; Bryan Kaehr; Jason L. Townson; Johanna Niklander; Riina Harjumäki; C. Jeffrey Brinker; Marjo Yliperttula
Three-dimensional (3D) cell cultures produce more in vivo-like multicellular structures such as spheroids that cannot be obtained in two-dimensional (2D) cell cultures. Thus, they are increasingly employed as models for cancer and drug research, as well as tissue engineering. It has proven challenging to stabilize spheroid architectures for detailed morphological examination. Here we overcome this issue using a silica bioreplication (SBR) process employed on spheroids formed from human pluripotent stem cells (hPSCs) and hepatocellular carcinoma HepG2 cells cultured in the nanofibrillar cellulose (NFC) hydrogel. The cells in the spheroids are more round and tightly interacting with each other than those in 2D cultures, and they develop microvilli-like structures on the cell membranes as seen in 2D cultures. Furthermore, SBR preserves extracellular matrix-like materials and cellular proteins. These findings provide the first evidence of intact hPSC spheroid architectures and similar fine structures to 2D-cultured cells, providing a pathway to enable our understanding of morphogenesis in 3D cultures.
Scientific Reports | 2018
Terisse Brocato; Eric N. Coker; Paul N. Durfee; Yu Shen Lin; Jason L. Townson; Edward F. Wyckoff; Vittorio Cristini; C. Jeffrey Brinker; Zhihui Wang
Nanoparticles have shown great promise in improving cancer treatment efficacy while reducing toxicity and treatment side effects. Predicting the treatment outcome for nanoparticle systems by measuring nanoparticle biodistribution has been challenging due to the commonly unmatched, heterogeneous distribution of nanoparticles relative to free drug distribution. We here present a proof-of-concept study that uses mathematical modeling together with experimentation to address this challenge. Individual mice with 4T1 breast cancer were treated with either nanoparticle-delivered or free doxorubicin, with results demonstrating improved cancer kill efficacy of doxorubicin loaded nanoparticles in comparison to free doxorubicin. We then developed a mathematical theory to render model predictions from measured nanoparticle biodistribution, as determined using graphite furnace atomic absorption. Model analysis finds that treatment efficacy increased exponentially with increased nanoparticle accumulation within the tumor, emphasizing the significance of developing new ways to optimize the delivery efficiency of nanoparticles to the tumor microenvironment.
ACS Nano | 2012
Carlee E. Ashley; Eric C. Carnes; Katharine Epler; David Padilla; Genevieve K Phillips; Robert Eric Castillo; Dan C. Wilkinson; Brian Wilkinson; Cameron Burgard; Robin M. Kalinich; Jason L. Townson; Bryce Chackerian; Cheryl L. Willman; David S. Peabody; Walker Wharton; C. Jeffrey Brinker
Advanced Healthcare Materials | 2012
Katharine Epler; David Padilla; Genevieve K Phillips; Peter Crowder; Robert Castillo; Dan C. Wilkinson; Brian Wilkinson; Cameron Burgard; Robin M. Kalinich; Jason L. Townson; Bryce Chackerian; Cheryl L. Willman; David S. Peabody; Walker Wharton; C. Jeffrey Brinker; Carlee E. Ashley; Eric C. Carnes
Advanced Healthcare Materials | 2012
Katharine Epler; David Padilla; Genevieve K Phillips; Peter Crowder; Robert Castillo; Dan C. Wilkinson; Brian Wilkinson; Cameron Burgard; Robin M. Kalinich; Jason L. Townson; Bryce Chackerian; Cheryl L. Willman; David S. Peabody; Walker Wharton; C. Jeffrey Brinker; Carlee E. Ashley; Eric C. Carnes
Archive | 2018
Bryan Kaehr; Kristin Meyer; Jason L. Townson